Immunotherapy combo increases progression-free survival in advanced melanoma patients
Sunday, May 31, 2015 - 09:30
in Health & Medicine
Treating advanced melanoma patients with either a combination of the immunotherapy drugs nivolumab and ipilimumab or nivolumab alone significantly increases progression-free survival over using ipilimumab alone, according to researchers.